All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Frontline ibrutinib + venetoclax in CLL: Results from a fixed duration cohort of the CAPTIVATE study

During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, What are the results from a fixed duration cohort of the CAPTIVATE study?

Frontline ibrutinib + venetoclax in CLL: Results from a fixed duration cohort of the CAPTIVATE study

In this video, Tam discusses results from the phase II CAPTIVATE study (NCT02910583) investigating frontline ibrutinib and venetoclax in a chronic lymphocytic leukemia (CLL) cohort. He reports a complete remission or complete remission with incomplete count recovery rate of 56% and measurable residual disease negativity in 78% of patients.

 

Share: